Figure 1.
Figure 1. Impaired IL-12p70 and TNF-α production in patients with SzS. Total PBMCs from healthy donors and patients with SzS were activated with anti-CD3 (A,C) or a mixture of LPS (1 μg/mL) and IFN-γ (500 IU/mL) (B,D). After 24 hours, supernatants were harvested and assayed for IL-12p70 (A,B) and TNF-α (C,D) production. (E) Total PBMCs from a healthy donor were activated as in panel A in the presence of a blocking mAb against CD40L (10 μg/mL) or an isotype-control mAb. The production of IL-12p70 after 24 hours is shown.

Impaired IL-12p70 and TNF-α production in patients with SzS. Total PBMCs from healthy donors and patients with SzS were activated with anti-CD3 (A,C) or a mixture of LPS (1 μg/mL) and IFN-γ (500 IU/mL) (B,D). After 24 hours, supernatants were harvested and assayed for IL-12p70 (A,B) and TNF-α (C,D) production. (E) Total PBMCs from a healthy donor were activated as in panel A in the presence of a blocking mAb against CD40L (10 μg/mL) or an isotype-control mAb. The production of IL-12p70 after 24 hours is shown.

Close Modal

or Create an Account

Close Modal
Close Modal